Ameriprise’s Terns Pharmaceuticals TERN Stock Holding History

Ameriprise’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-118,246	Closed	-$6.23M	–	4251
2026 Q1	$6.23M	Sell	118,246 -1,776,135	-94%	-$73M	﹤0.01%	2295
2025 Q4	$76.5M	Buy	+1,894,381	New	+$43.8M	0.02%	667
2025 Q2	–	Sell	-19,166	Closed	-$52.9K	–	4124
2025 Q1	$52.9K	Buy	+19,166	New	+$78.3K	﹤0.01%	3938

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ameriprise's TERN Position: Q2 2026 in Review

Ameriprise sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 118,246 shares — an estimated $6.23M sold.

Ameriprise first reported a position in TERN in Q1 2025 and held it in 3 quarters. The position peaked at $76.5M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Ameriprise reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Ameriprise sold 118,246 Terns Pharmaceuticals shares in Q2 2026, an estimated $6.23M.
Ameriprise first reported a position in Terns Pharmaceuticals in Q1 2025 and held it in 3 quarters.
Ameriprise's Terns Pharmaceuticals position peaked at $76.5M in Q4 2025.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.